Business Description
Alterity Therapeutics Ltd
ISIN : US02155X2053
Share Class Description:
ATHE: ADRTotal Employee Number:
9Description
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 502.05 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32.8 | |||||
3-Year EPS without NRI Growth Rate | 32.2 | |||||
3-Year FCF Growth Rate | 29.6 | |||||
3-Year Book Growth Rate | -32 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -228.38 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.25 | |||||
9-Day RSI | 59.61 | |||||
14-Day RSI | 59.41 | |||||
3-1 Month Momentum % | 29.11 | |||||
6-1 Month Momentum % | 35.1 | |||||
12-1 Month Momentum % | 3.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 21.98 | |||||
Quick Ratio | 21.98 | |||||
Cash Ratio | 19.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -55.9 | |||||
Shareholder Yield % | -50.45 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year ROIIC % | 211.39 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
PB Ratio | 2.29 | |||||
Price-to-Tangible-Book | 2.28 | |||||
EV-to-EBIT | -6.07 | |||||
EV-to-EBITDA | -6.14 | |||||
EV-to-Forward-Revenue | 5.13 | |||||
EV-to-FCF | -4.23 | |||||
| Price-to-Net-Current-Asset-Value | 2.28 | |||||
| Price-to-Net-Cash | 2.72 | |||||
Earnings Yield (Greenblatt) % | -16.47 | |||||
FCF Yield % | -14.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATHE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alterity Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | - | ||
| Beta | 0.0358 | ||
| 3-Year Sharpe Ratio | 0.4 | ||
| 3-Year Sortino Ratio | 1.14 | ||
| Volatility % | 56.23 | ||
| 14-Day RSI | 59.41 | ||
| 14-Day ATR ($) | 0.273216 | ||
| 20-Day SMA ($) | 4.45605 | ||
| 12-1 Month Momentum % | 3.73 | ||
| 52-Week Range ($) | 2.66 - 7 | ||
| Shares Outstanding (Mil) | 0.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alterity Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alterity Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-20 11:00 | In 144 days | ||
| First quarter earnings results for 2026 | 2026-10-30 | In 122 days | ||
| Annual report for 2026 | 2026-08-28 | In 59 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 59 days | ||
| Third quarter earnings results for 2026 | 2026-04-30 | 4.56 (+0.88%) | ||
| Second quarter earnings results for 2026 | 2026-02-25 | 3.33 (+0.79%) | ||
| General meeting for 2025 | 2025-11-21 11:00 | 3.52 (+0.28%) | ||
| Bell Potter Healthcare Virtual Conference | 2025-11-18 18:30 | 3.79 (+0.11%) | ||
| First quarter earnings results for 2025 | 2025-10-30 | 4.70 (-3.18%) | ||
| Annual report for 2025 | 2025-08-29 | 5.02 (+0.44%) |
Show
Entries
Alterity Therapeutics Ltd Frequently Asked Questions
What is Alterity Therapeutics Ltd(ATHE)'s stock price today?
The current price of ATHE is $4.84. The 52 week high of ATHE is $7.00 and 52 week low is $2.66.
When is next earnings date of Alterity Therapeutics Ltd(ATHE)?
The next earnings date of Alterity Therapeutics Ltd(ATHE) is 2026-08-28 Est..
Does Alterity Therapeutics Ltd(ATHE) pay dividends? If so, how much?
Alterity Therapeutics Ltd(ATHE) does not pay dividend.
Guru Commentaries on NAS:ATHE
No articles.
Press Release
Articles on Alterity Therapeutics Ltd
No articles.
Headlines
See More- 1
Jun 09, 2026
Alterity, FDA agree on phase 3 program for multiple system atrophy asset ATH434
Seeking Alpha • 6:34am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers